Loading data for PPCB — first visit, this takes a few seconds.
Propanc Biopharma Inc. (PPCB)
NasdaqCM: PPCB
· Echtzeitkurs · USD
1.16
+0.01 (0.87%)
Zum Schluss: Aug 18, 2026, 8:00 PM
1.21
+3.97%
Vorbörslich: 8:04 AM
Propanc Biopharma Inc. (PPCB) Stock Price, Analysis & Data
0.87% (1D)
Keine Daten verfügbar
| Geld | 0.83 |
| Marktkapitalisierung | 2.64 Mio |
| Umsatz (TTM) | n/a |
| Nettogewinn (TTM) | -19.29 Mio |
| Beta | 3.27 |
| EPS (ttm) | 570.5 |
| KGV (TTM) | 0 |
| Forward-KGV | n/a |
| KBV (TTM) | 0.10 |
| KUV (TTM) | n/a |
| Earnings Date | n/a |
| Brief | 1.45 |
| Volumen | 29,621 |
| Ø Vol. (20D) | 3,929,150 |
| Eröffnung | 1.12 |
| Vortagesschluss | 1.15 |
| Tagesspanne | 1.10 - 1.19 |
| 52-Wk Range | 0.95 - 142.25 |
| Analyst | n/a |
| Kursziel | n/a |
| Dividenden | n/a |
| Ex-Dividenden-Datum | n/a |
Über PPCB
Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. The company has a research and collaboration agreemen...
Branche Biotechnology
Sektor Healthcare
IPO Datum Jan 7, 2013
Mitarbeiter 1
Börse NasdaqCM
Tickersymbol PPCB
Website https://www.propanc.com
Finanzielle Entwicklung
Im Jahr 2025 betrug der Umsatz von Propanc Biopharma 0, ein Anstieg von undefined% im Vergleich zum Vorjahr (0). Der Gewinn lag bei -58.92 Mio, ein Anstieg von 3,136.6 %.
Finanzberichte